Lucid Diagnostics has secured a VA contract for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer screening for more than 9 million veterans through the federal supply schedule at Medicare-aligned pricing.
A 44-metabolite blood test signature identified by Mass General Brigham and Einstein researchers improved type 2 diabetes risk prediction in a study of over 23,000 participants, according to Nature Medicine.
A longitudinal study finds blood-based biomarkers more sensitive than PET scans in detecting obesity's impact on Alzheimer's pathology.
The biotechnology company's integrated screening approach combines whole-genome sequencing, imaging, and multiple biomarker tests to enable early detection.
The new PCR test detects and quantifies hepatitis delta virus (HDV)-specific RNA in human EDTA plasma and serum.
The cobas BV/CV assay aims to improve diagnostic accuracy over traditional microscopy and pH testing methods for symptomatic patients.
The test is being developed to differentiate between adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis at the point of care.
The test measures two sugar alcohols to detect SORD-related neuropathy, which standard genetic tests sometimes miss.
Research finds lysophosphatidylcholines either promote or protect against disease depending on APOE ε4 gene status, with implications for personalized treatments.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The eight-minute test also shortened hospital stays by nearly two days at Froedtert Hospital, reinforcing previous multi-site evidence.